Collegium Pharmaceutical, Inc. (COLL) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in a research note issued to investors on Wednesday, November 8th. The brokerage currently has a $21.00 price objective on the specialty pharmaceutical company’s stock.

COLL has been the topic of several other reports. Piper Jaffray Companies set a $14.00 target price on shares of Collegium Pharmaceutical and gave the stock a buy rating in a research report on Tuesday, July 25th. Needham & Company LLC restated a buy rating and set a $25.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, October 6th. Jefferies Group LLC restated a buy rating and set a $15.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, October 6th. Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a sell rating to a hold rating in a research report on Monday, August 14th. Finally, BidaskClub lowered shares of Collegium Pharmaceutical from a hold rating to a sell rating in a research report on Friday, August 4th. Two equities research analysts have rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The stock has an average rating of Buy and an average price target of $19.33.

Shares of Collegium Pharmaceutical (COLL) opened at $15.52 on Wednesday. Collegium Pharmaceutical has a 1-year low of $7.37 and a 1-year high of $19.21.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.28. The firm had revenue of $11.95 million during the quarter, compared to analysts’ expectations of $5.31 million. Collegium Pharmaceutical had a negative net margin of 447.83% and a negative return on equity of 77.11%. The firm’s revenue for the quarter was up 2814.6% on a year-over-year basis. During the same period in the prior year, the company posted ($1.13) earnings per share. research analysts expect that Collegium Pharmaceutical will post -2.56 earnings per share for the current fiscal year.

In other Collegium Pharmaceutical news, insider Alison B. Fleming sold 4,601 shares of the stock in a transaction that occurred on Tuesday, November 21st. The shares were sold at an average price of $17.25, for a total transaction of $79,367.25. Following the transaction, the insider now owns 28,513 shares of the company’s stock, valued at $491,849.25. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Michael Thomas Heffernan sold 50,000 shares of the firm’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $15.53, for a total transaction of $776,500.00. Following the completion of the transaction, the chief executive officer now directly owns 558,987 shares in the company, valued at approximately $8,681,068.11. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 58,630 shares of company stock worth $924,360. 25.76% of the stock is owned by company insiders.

Several hedge funds have recently modified their holdings of the company. Sectoral Asset Management Inc raised its stake in shares of Collegium Pharmaceutical by 41.4% in the 2nd quarter. Sectoral Asset Management Inc now owns 1,808,750 shares of the specialty pharmaceutical company’s stock valued at $22,627,000 after acquiring an additional 529,503 shares during the period. Macquarie Group Ltd. raised its stake in shares of Collegium Pharmaceutical by 18.9% in the 3rd quarter. Macquarie Group Ltd. now owns 1,329,979 shares of the specialty pharmaceutical company’s stock valued at $13,951,000 after acquiring an additional 211,288 shares during the period. Morgan Stanley grew its holdings in Collegium Pharmaceutical by 684.8% during the 1st quarter. Morgan Stanley now owns 885,268 shares of the specialty pharmaceutical company’s stock valued at $8,906,000 after purchasing an additional 772,464 shares in the last quarter. Vanguard Group Inc. grew its holdings in Collegium Pharmaceutical by 7.8% during the 1st quarter. Vanguard Group Inc. now owns 806,539 shares of the specialty pharmaceutical company’s stock valued at $8,113,000 after purchasing an additional 58,398 shares in the last quarter. Finally, Prudential Financial Inc. grew its holdings in Collegium Pharmaceutical by 62.8% during the 3rd quarter. Prudential Financial Inc. now owns 557,050 shares of the specialty pharmaceutical company’s stock valued at $5,843,000 after purchasing an additional 214,860 shares in the last quarter. 79.98% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Collegium Pharmaceutical, Inc. (COLL) Earns Buy Rating from HC Wainwright” was first posted by BBNS and is owned by of BBNS. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://baseballnewssource.com/markets/collegium-pharmaceuticals-coll-buy-rating-reaffirmed-at-hc-wainwright/1768044.html.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Manny Machado Could Change Positions or Uniforms
Manny Machado Could Change Positions or Uniforms
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot


Leave a Reply

 
© 2006-2017 BBNS.